Ensysce Biosciences Inc (ENSC) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company's financial performance is extremely poor, with significant revenue and net income declines. Technical indicators are bearish, and there are no positive trading signals or catalysts to suggest a reversal. The lack of news, analyst ratings, and congress trading data further supports the conclusion that this stock is not suitable for investment at this time.

Technical Analysis

The MACD is slightly positive, but RSI is neutral, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 0.472, with resistance at 0.619 and support at 0.325. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

NULL identified. No recent news, trading trends, or significant signals to indicate positive momentum.

Neutral/Negative Catalysts

EPS also fell significantly (-229.00%). Technical indicators are bearish, and there is no recent activity from hedge funds, insiders, or congress members.

Financial Performance

In Q3 2025, revenue dropped to $493,104 (-85.58% YoY), net income fell to -$3,729,128 (-663.51% YoY), and EPS declined to -1.29 (-229.00% YoY). Gross margin remained stable at 100%. Overall, financial performance is extremely poor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

Analyst Rating

Wall Street analysts forecast ENSC stock price to rise

Buy

Hold

Sell

Current: 0.395

Low

Averages

High